NovoCure (NVCR) Stock Price, News & Analysis

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NVCR shares.
View NVCR analyst ratings or view top-rated stocks.

9 analysts have issued 12 month price targets for NovoCure's stock. Their NVCR share price targets range from $15.00 to $51.00. On average, they expect the company's share price to reach $31.13 in the next year. This suggests a possible upside of 157.4% from the stock's current price.
View analysts price targets for NVCR or view top-rated stocks among Wall Street analysts.

NovoCure's stock was trading at $14.93 on January 1st, 2024. Since then, NVCR stock has decreased by 19.0% and is now trading at $12.09.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our NVCR earnings forecast.

NovoCure will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

NovoCure Limited (NASDAQ:NVCR) announced its quarterly earnings results on Thursday, February, 22nd. The medical equipment provider reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.08. The medical equipment provider earned $133.80 million during the quarter, compared to analysts' expectations of $133.80 million. NovoCure had a negative net margin of 40.65% and a negative trailing twelve-month return on equity of 51.63%. The company's revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.36) EPS.

ETFs with the largest weight of NovoCure (NASDAQ:NVCR) stock in their portfolio include Amplify BlueStar Israel Technology ETF (ITEQ), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares U.S. Medical Devices ETF (IHI).First Trust Nasdaq Pharmaceuticals ETF (FTXH).

17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy (VNOM), Roku (ROKU), Salesforce (CRM) and Block (SQ).

NovoCure's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Taylor Frigon Capital Management LLC (0.12%), Counterpoint Mutual Funds LLC (0.04%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends.

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.